Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VANI Stock Forecast 2026-2027
$1.27
Current Price
$92.65M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to VANI Price Targets
+451.2%
To High Target of $7.00
+215.0%
To Median Target of $4.00
+215.0%
To Low Target of $4.00
VANI Price Momentum
-3.1%
1 Week Change
-5.9%
1 Month Change
+5.8%
1 Year Change
+3.3%
Year-to-Date Change
-33.9%
From 52W High of $1.92
+40.3%
From 52W Low of $0.90
📊 TOP ANALYST CALLS
Did VANI Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Vivani is one of their latest high-conviction picks.
Latest VANI Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, VANI has a bullish consensus with a median price target of $4.00 (ranging from $4.00 to $7.00). The overall analyst rating is N/A (N/A/10). Currently trading at $1.27, the median forecast implies a 215.0% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Ashok Kumar at ThinkEquity, projecting a 451.2% upside. Conversely, the most conservative target is provided by Yi Chen at HC Wainwright & Co., suggesting a 215.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VANI Analyst Ratings
3
Buy
0
Hold
0
Sell
VANI Price Target Range
Low
$4.00
Average
$4.00
High
$7.00
Current: $1.27
Latest VANI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VANI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 2, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $4.00 |
| May 19, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $4.00 |
| Apr 16, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $4.00 |
| Apr 4, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $4.00 |
| Mar 26, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $4.00 |
| Mar 13, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $4.00 |
| Nov 7, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Initiates | $3.00 |
| Dec 5, 2022 | ThinkEquity | Ashok Kumar | Buy | Initiates | $7.00 |
Vivani Medical Inc. (VANI) Competitors
The following stocks are similar to Vivani based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Vivani Medical Inc. (VANI) Financial Data
Vivani Medical Inc. has a market capitalization of $92.65M with a P/E ratio of -3.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -265.0%.
Valuation Metrics
Market Cap
$92.65M
Enterprise Value
$109.04M
P/E Ratio
-3.0x
PEG Ratio
-3.7x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+2.8%
Current Ratio
0.6x
Debt/Equity
1,397.5x
ROE
-265.0%
ROA
-50.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Vivani Medical Inc. (VANI) Business Model
About Vivani Medical Inc.
What They Do
Develops innovative healthcare solutions in biotechnology.
Business Model
Vivani Medical Inc. generates revenue by developing and commercializing advanced implantable medical devices aimed at treating chronic diseases and sensory deficits. Their focus on bioelectronics allows them to create long-term therapeutic solutions that enhance patient outcomes, which can lead to partnerships with healthcare providers and sales of their devices.
Additional Information
Vivani Medical operates at the forefront of bioengineering and healthcare, with implications for various medical fields such as neuroscience and chronic disease management. Their work in bioelectronic medicine positions them as key players in addressing significant health challenges, indicating strong growth potential in the evolving medical technology landscape.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
37
CEO
Dr. Adam Mendelsohn Ph.D.
Country
United States
IPO Year
2022
Website
www.vivani.comVivani Medical Inc. (VANI) Latest News & Analysis
Latest News
Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results
2 months ago
Quick Summary
The company will start a Phase 1 clinical study of a semaglutide implant for weight management in H1 2026, with plans for a Phase 2 study pending results and regulatory feedback.
Why It Matters
The initiation of a Phase 1 clinical study for a weight management implant indicates potential future revenue streams and market opportunities, impacting the company's growth outlook and stock valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Vivani Medical, Inc. closed a registered direct offering of 6M shares at $1.62 each and a private placement of 3.7M shares, raising approximately $15.7M in gross proceeds.
Why It Matters
Vivani Medical raised $15.7 million through stock offerings, indicating financial backing for its drug development. This can enhance growth prospects and influence stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Insiders Are Buying These 3 Stocks Hand Over Fist
2 months ago
Quick Summary
Insider buying may indicate a potential company turnaround, reflecting management's confidence in the firm's future performance.
Why It Matters
Insider buying often signals confidence in a company’s future, potentially indicating a turnaround and influencing investor sentiment and stock performance.
Source: 24/7 Wall Street
Market Sentiment:
Positive
Quick Summary
Vivani Medical has priced a direct offering of 6M shares at $1.62 each and a private placement of 3.7M shares at the same price, aiming for gross proceeds of $15.7M, closing around October 28, 2025.
Why It Matters
Vivani Medical's stock offering indicates a strategy to raise $15.7 million, potentially strengthening its financial position for development. Chairman's participation may signal confidence in the company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The Company plans to announce a new record date soon.
Why It Matters
A new record date could indicate upcoming corporate actions like dividends or stock splits, potentially impacting share value and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Vivani Medical, Inc. (NASDAQ: VANI) will present at the Emerging Growth Conference 86 on September 25, 2025, highlighting its development of ultra long-acting drug implants.
Why It Matters
Vivani Medical's presentation at a key conference highlights its innovative drug delivery technology, potentially attracting investors and impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About VANI Stock
What is Vivani Medical Inc.'s (VANI) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Vivani Medical Inc. (VANI) has a median price target of $4.00. The highest price target is $7.00 and the lowest is $4.00.
Is VANI stock a good investment in 2026?
According to current analyst ratings, VANI has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.27. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VANI stock?
Wall Street analysts predict VANI stock could reach $4.00 in the next 12 months. This represents a 215.0% increase from the current price of $1.27. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Vivani Medical Inc.'s business model?
Vivani Medical Inc. generates revenue by developing and commercializing advanced implantable medical devices aimed at treating chronic diseases and sensory deficits. Their focus on bioelectronics allows them to create long-term therapeutic solutions that enhance patient outcomes, which can lead to partnerships with healthcare providers and sales of their devices.
What is the highest forecasted price for VANI Vivani Medical Inc.?
The highest price target for VANI is $7.00 from Ashok Kumar at ThinkEquity, which represents a 451.2% increase from the current price of $1.27.
What is the lowest forecasted price for VANI Vivani Medical Inc.?
The lowest price target for VANI is $4.00 from Yi Chen at HC Wainwright & Co., which represents a 215.0% increase from the current price of $1.27.
What is the overall VANI consensus from analysts for Vivani Medical Inc.?
The overall analyst consensus for VANI is bullish. Out of 2 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $4.00.
How accurate are VANI stock price projections?
Stock price projections, including those for Vivani Medical Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 4:45 AM UTC